Separation and culture method of circulating tumor cells
Through the enrichment and culture method of circulating tumor cells, basal culture medium and serum surrogate, combined with growth factors, etc., the problems of small number of circulating tumor cells and phenotype changes are solved, and rapid isolation and culture are achieved, and research and development are provided. Diagnostic tools.
Patent Information
- Application Number
- CN202311737329.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-15
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively extract and culture circulating tumor cells, especially due to their small number and phenotypic heterogeneity and dynamic changes, resulting in huge difficulties in research and diagnosis.
A method of enrichment and culture of circulating tumor cells, including collecting samples, enriching circulating tumor cells, initial culture using basal culture medium and serum or their substitutes, and maintaining culture by replacing the culture medium, combining growth factors and Additives such as antibiotics, optimize culture conditions.
The rapid and easy isolation and culture of circulating tumor cell lines is achieved, and a large number of preserved and amplified cells are obtained, providing tools for in-depth research and new drug development to help uncover tumor metastasis mechanisms and diagnostic methods.
Smart Images

Figure SMS_1 
Figure HDA0004612294310000011 
Figure HDA0004612294310000012
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cell culture, and in particular relates to a method for separating and culturing circulating tumor cells derived from ovarian yolk sac tumor. Background Art
[0002] Malignant tumors are one of the major threats to human health. The vast majority of tumor-related deaths are caused by tumor recurrence and metastasis. However, the mechanism of tumor metastasis is not fully understood. Revealing the mechanism of tumor recurrence and metastasis is crucial to the development of new diagnostic and therapeutic methods. Solid tumors will continuously shed tumor cells, and some of the shed cells can enter the blood circulation system and are called circulating tumor cells. Circulating tumor cells are the key mediators of malignant tumor metastasis through the blood. If the specific markers and biological characteristics of circulating tumor cells can be determined, it is expected to establish new methods for diagnosing tumor metastasis risk, and even develop specific drugs to reduce the incidence of tumor metastasis.
[0003] Because the number of circulating tumor cells is very small. For most cancer patients, the number of circulating tumor cells in every 10mL of peripheral blood is less than 10. However, the same volume of peripheral blood contains tens of millions of blood cells, which brings great difficulties to the extraction and study of circulating tumor cells. Because the functions and phenotypes of circulating tumor cells are different from those of solid tumor cells in situ. Circulating tumor cells have undergone a series of changes, including epithelial-mesenchymal transition, which enables them to adapt to anchorless growth and shear forces formed by blood flow. Not only that, studies have shown that the phenotype of circulating tumor cells is heterogeneous and dynamically changing. This brings greater difficulties to the study of circulating tumor cells.
[0004] As an example of a malignant tumor, germ cell tumor (GCT) originates from primordial germ cells, mainly including yolk sac tumor (YST), dysgerminoma, teratoma, embryonal carcinoma, polyembryonic carcinoma and non-gestational choriocarcinoma. Clinically, mixed types consisting of two or more histological subtypes are common. It occurs at an early age and is common in the gonads (ovaries or testicles). It can also be seen in the vagina, mediastinum, retroperitoneum and brain. GCT is sensitive to chemotherapy. Since the application of cisplatin-based chemotherapy, the prognosis of patients has been significantly improved. Most patients can survive for a long time after regular treatment even if distant metastasis occurs at the onset of the disease. However, about 10% to 20% of patients relapse, often accompanied by chemotherapy resistance, poor treatment effect, and clinical treatment is very difficult. Recurrent GCT is often yolk sac tumor or contains yolk sac tumor components.
[0005] If it is possible to establish a circulating tumor cell line by extracting circulating tumor cells and culturing them in vitro, it will be of great help in promoting research on tumor metastasis and treatment. Summary of the invention
[0006] In order to solve at least one of the above problems, the present disclosure provides a method for enriching and culturing circulating tumor cells and applications thereof.
[0007] According to one aspect of the present disclosure, a method for enriching and culturing circulating tumor cells is provided, the method comprising the following steps:
[0008] 1) Collect samples;
[0009] 2) enriching circulating tumor cells from the sample;
[0010] 3) using a first culture medium to resuspend the enriched circulating tumor cells and culture them to obtain a first culture product, wherein the first culture medium comprises a basal culture medium and 5% to 20% serum; and
[0011] 4) Using a second culture medium to replace the first culture medium for maintenance culture to obtain a second culture product, wherein the second culture medium comprises a basal culture medium and 5% to 20% of a serum replacement.
[0012] In some embodiments, the sample is from a subject who has or has had a solid tumor, a soft tissue tumor, a hematopoietic tumor, a glandular tumor, or a metastatic tumor.
[0013] In some embodiments, the sample comprises a body fluid or a derivative thereof. In some embodiments, the sample may be selected from blood, plasma, serum, lymph, saliva, urine, sweat or ascites. In some embodiments, the sample may be ascites.
[0014] In some embodiments, the circulating tumor cells (CTCs) are metastatic CTCs.
[0015] In some embodiments, the CTC may include, but is not limited to, acute leukemia cells, acute T-cell leukemia cells, acute lymphocytic leukemia cells, acute myeloid leukemia cells, myeloblastic leukemia cells, promyelocytic leukemia cells, myelomonocytic leukemia cells, monocytic leukemia cells, erythroleukemia cells, chronic leukemia cells, chronic myeloid (granulocytic) leukemia cells, chronic lymphocytic leukemia cells, polycythemia vera cells, lymphoma cells, multiple myeloma cells, Waldenstrom's macroglobulinemia cells, heavy chain disease cells, sarcoma cells, fibrosarcoma cells, myxosarcoma cells, liposarcoma cells, chondrosarcoma cells, osteoblastic sarcoma cells, lymphangiosarcoma cells, mesothelioma cells, Ewing's tumor cells, cell), leiomyosarcoma cell, rhabdomyosarcoma cell, colon cancer cell, colorectal cancer cell, pancreatic cancer cell, breast cancer cell, ovarian cancer cell, ovarian yolk sac tumor cell, prostate cancer cell, castration resistant prostate cancer cell, squamous cell carcinoma cell, basal cell carcinoma cell, adenocarcinoma cell, sweat gland carcinoma cell, sebaceous gland carcinoma cell, papillary carcinoma cell, papillary adenocarcinoma cell, cystadenocarcinoma cell, medullary carcinoma cell, bronchogenic cell, renal cell carcinoma cell, hepatoma cell, bile duct carcinoma cell, choriocarcinoma cell, seminoma cell, embryonal carcinoma cell, Wilms' tumor cell cell), cervical cancer cell, uterine cancer cell, testicular tumor cell, lung cancer cell, small cell lung cancer cell, bladder cancer cell, epithelial cancer cell, glioma cell, craniopharyngioma cell, ependymoma cell, pinealoma cell, hemangioblastoma cell, acoustic neuroma cell, oligodendroglioma cell, meningioma cell, melanoma cell, neuroblastoma cell, retinoblastoma cell, endometrial cancer cell, non-small cell lung cancer cell, head and neck cancer cell, or renal cancer cell.
[0016] In a specific embodiment, the circulating tumor cell (CTC) is an ovarian yolk sac tumor cell.
[0017] In some embodiments, the enrichment can be performed in a manner known in the art, for example, centrifugation based on cell density, membrane filtration based on cell size, magnetic beads targeting circulating tumor cells, or microfluidics technology can be used to enrich circulating tumor cells in the sample.
[0018] In some embodiments, the basal culture medium can be selected from M199 culture medium, DMEM / F12 culture medium, IMDM culture medium, DMEM culture medium, high glucose DMEM culture medium or Knockout-DMEM culture medium.
[0019] In some embodiments, the first culture medium and / or the second culture medium comprises high glucose DMEM (H-DMEM) medium.
[0020] In some embodiments, the first culture medium comprises 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19 or 20% (volume ratio) fetal bovine serum.
[0021] In some embodiments, the second culture medium and / or the second culture medium comprises Knockout-DMEM medium.
[0022] In some embodiments, the second culture medium may include KnockOut TM Serum replacement, such as KnockOut TM Serum replacement.
[0023] In some embodiments, the first culture medium and / or the second culture medium may further comprise growth factors. In some embodiments, the first culture medium and / or the second culture medium may comprise, for example, growth factors including: one or more of epidermal growth factor (EGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), fibroblast growth factor (FGF), stem cell factor (SCF), insulin-like growth factor (IGF), and transforming growth factor-β (TGF-β).
[0024] In some embodiments, the first culture medium and / or the second culture medium may contain 10 to 50 ng / mL of basic fibroblast growth factor.
[0025] In some embodiments, the first culture medium and / or the second culture medium may contain 10 ng / mL, 11 ng / mL, 12 ng / mL, 13 ng / mL, 14 ng / mL, 15 ng / mL, 16 ng / mL, 17 ng / mL, 18 ng / mL, 19 ng / mL, 20 ng / mL, 21 ng / mL, 22 ng / mL, 23 ng / mL, 24 ng / mL, 25 ng / mL, 26 ng / mL, 27 ng / mL, 28 ng / mL, 29 ng / mL. 5 ng / mL, 50 ng / mL, 51 ng / mL, 52 ng / mL, 53 ng / mL, 54 ng / mL, 55 ng / mL, 56 ng / mL, 57 ng / mL, 58 ng / mL, 59 ng / mL, 60 ng / mL, 61 ng / mL, 62 ng / mL, 63 ng / mL, 64 ng / mL, 65 ng / mL, 66 ng / mL, 67 ng / mL, 68 ng / mL, 69 ng / mL or 70 ng / mL of basic fibroblast growth factor.
[0026] In some embodiments, the first culture medium and / or the second culture medium may contain 10 to 50 ng / mL of epidermal growth factor.
[0027] In some embodiments, the first culture medium and / or the second culture medium may contain 10 ng / mL, 11 ng / mL, 12 ng / mL, 13 ng / mL, 14 ng / mL, 15 ng / mL, 16 ng / mL, 17 ng / mL, 18 ng / mL, 19 ng / mL, 20 ng / mL, 21 ng / mL, 22 ng / mL, 23 ng / mL, 24 ng / mL, 25 ng / mL, 26 ng / mL, 27 ng / mL, 28 ng / mL, 29ng / mL, 30ng / mL, 31ng / mL, 32ng / mL, 33ng / mL, 34ng / mL, 35ng / mL, 36ng / mL, 37ng / mL, 38ng / mL, 39ng / mL, 40n g / mL, 41ng / mL, 42ng / mL, 43ng / mL, 44ng / mL, 45ng / mL, 46ng / mL, 47ng / mL, 48ng / mL, 49ng / mL, or 50ng / mL of epidermal growth factor.
[0028] In some embodiments, the first culture medium and / or the second culture medium may further contain antibiotics, for example, 0% to 5% (volume ratio) of penicillin-streptomycin.
[0029] In some embodiments, the first culture medium and / or the second culture medium contains 0%, 1%, 2%, 3%, 4% or 5% (volume ratio) of a penicillin-streptomycin mixture.
[0030] In some embodiments, the first culture medium and / or the second culture medium may further contain small molecule additives, such as sodium pyruvate, endothelin-1, transferrin, cholesterol, etc.
[0031] In some embodiments, the first culture medium and / or the second culture medium may further contain 0.1 mM to 10 mM sodium pyruvate.
[0032] In some embodiments, the first culture medium and / or the second culture medium may further comprise 0.1mMmM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.1mM, 1.2mM, 1.3mM, 1.4mM, 1.5mM, 1.6mM, 1.7mM, 1.8mM, 1.9mM, 2mM, 2.1mM. , 2.2mM, 2.3mM, 2.4mM, 2.5mM, 2.6mM, 2.7mM, 2.8mM, 2.9mM, 3mM, 3.1mM, 3.2mM, 3.3mM, 3.4mM, 3.5mM, 3.6mM, 3.7mM, 3.8mM, 3.9mM, 4mM, 4.1mM, 4.2mM, 4.3mM, 4.4mM, 4.5mM, 4.6mM, 4.7mM, 4. 8mM, 4.9mM, 5mM, 5.1mM, 5.2mM, 5.3mM, 5.4mM, 5.5mM, 5.6mM, 5.7mM, 5.8mM, 5.9mM, 6mM, 6.1mM , 6.2mM, 6.3mM, 6.4mM, 6.5mM, 6.6mM, 6.7mM, 6.8mM, 6.9mM, 7mM, 7.1mM, 7.2mM, 7.3mM, 7.4mM, 7 .5mM, 7.6mM, 7.7mM, 7.8mM, 7.9mM, 8mM, 8.1mM, 8.2mM, 8.3mM, 8.4mM, 8.5mM, 8.6mM, 8.7mM, 8. 8mM, 8.9mM, 9mM, 9.1mM, 9.2mM, 9.3mM, 9.4mM, 9.5mM, 9.6mM, 9.7mM, 9.8mM, 9.9mM or 10mM sodium pyruvate.
[0033] In some embodiments, the first culture medium and / or the second culture medium may further contain 1 mM sodium pyruvate.
[0034] In some embodiments, the first culture medium and / or the second culture medium may further comprise amino acids. Exemplary amino acids include essential amino acids such as, for example, phenylalanine, valine, threonine, tryptophan, isoleucine, methionine, leucine, lysine, and histidine; and other amino acids such as arginine, cysteine, glycine, glutamine, proline, serine, tyrosine, alanine, asparagine, aspartic acid, and glutamic acid.
[0035] In some embodiments, the first culture medium and / or the second culture medium may further contain 0.1 mM to 10 mM glutamine.
[0036] In some embodiments, the first culture medium and / or the second culture medium may further comprise 0.1mMmM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.1mM, 1.2mM, 1.3mM, 1.4mM, 1.5mM, 1.6mM, 1.7mM, 1.8mM, 1.9mM, 2mM, 2.1mM. , 2.2mM, 2.3mM, 2.4mM, 2.5mM, 2.6mM, 2.7mM, 2.8mM, 2.9mM, 3mM, 3.1mM, 3.2mM, 3.3mM, 3.4mM, 3.5mM, 3.6mM, 3.7mM, 3.8mM, 3.9mM, 4mM, 4.1mM, 4.2mM, 4.3mM, 4.4mM, 4.5mM, 4.6mM, 4.7mM, 4. 8mM, 4.9mM, 5mM, 5.1mM, 5.2mM, 5.3mM, 5.4mM, 5.5mM, 5.6mM, 5.7mM, 5.8mM, 5.9mM, 6mM, 6.1mM , 6.2mM, 6.3mM, 6.4mM, 6.5mM, 6.6mM, 6.7mM, 6.8mM, 6.9mM, 7mM, 7.1mM, 7.2mM, 7.3mM, 7.4mM, 7 .5mM, 7.6mM, 7.7mM, 7.8mM, 7.9mM, 8mM, 8.1mM, 8.2mM, 8.3mM, 8.4mM, 8.5mM, 8.6mM, 8.7mM, 8.8mM, 8.9mM, 9mM, 9.1mM, 9.2mM, 9.3mM, 9.4mM, 9.5mM, 9.6mM, 9.7mM, 9.8mM, 9.9mM or 10mM glutamine.
[0037] In some embodiments, the first culture medium and / or the second culture medium may further contain 1 mM glutamine.
[0038] In some embodiments, the serum comprises fetal bovine serum, newborn calf serum, calf serum, human serum, horse serum, porcine serum, rabbit serum, goat serum, or rabbit serum.
[0039] In some embodiments, the serum is fetal bovine serum.
[0040] In some embodiments, the serum replacement comprises KnockOut TM Serum replacement, N2 or B27.
[0041] In some embodiments, the serum replacement is KnockOut TM Serum replacement.
[0042] In some embodiments, the first culture medium may include: H-DMEM culture medium, 5% to 20% FBS, 10 to 50 ng / mL FGF, 10 to 50 ng / mL EGF, 0.1 to 10 mM sodium pyruvate, 0.1 to 10 mM L-glutamine and 0% to 5% penicillin-streptomycin mixture.
[0043] In some embodiments, the first culture medium may contain: H-DMEM culture medium, 10% FBS, 20 ng / mL FGF, 20 ng / mL EGF, 1 mM sodium pyruvate, 1 mM L-glutamine and 2% penicillin-streptomycin mixture.
[0044] In some embodiments, the second culture medium may include: knockout-DMEM culture medium, 5% to 20% KnockOut TM serum replacement (KSR), 10-50 ng / mL FGF, 10-50 ng / mL EGF, 0.1-10 mM sodium pyruvate and 0.1-10 mM L-glutamine.
[0045] In some embodiments, the second culture medium may include: knockout-DMEM culture medium, 10% KnockOut TM serum replacement (KSR), 20 ng / mL FGF, 20 ng / mL EGF, 1 mM sodium pyruvate, and 1 mM L-glutamine.
[0046] In some embodiments, in step 3) of the method, the culturing time is 10 to 36 hours.
[0047] In some embodiments, in the step 3) of the method, the culturing time is 10h, 11h, 12h, 13h, 14h, 15h, 16h, 17h, 18h, 19h, 20h, 21h, 22h, 23h, 24h, 25h, 26h, 27h, 28h, 29h, 30h, 31h, 32h, 33h, 34h, 35h or 36h.
[0048] In some embodiments, in step 3) of the method, the culturing time is 24 hours.
[0049] In some embodiments, in step 3) of the method, after culturing with the first culture medium for 10 to 36 hours, the first culture medium is replaced with the second culture medium for maintenance culture.
[0050] In some embodiments, the culture medium used in the present disclosure is sterilized by filtration, for example, by using a filter with a pore size of 0.22 μm.
[0051] In some embodiments, the method may further include the following steps:
[0052] 5) After the second culture product is digested with trypsin, it is resuspended in the first culture medium and cultured;
[0053] 6) using the second culture medium to replace the first culture medium for maintenance culture;
[0054] 7) Optionally, repeat steps 5) and 6).
[0055] In some embodiments, in step 5), the culture is performed for 10 to 36 hours, and then the first culture medium is replaced with the second culture medium for maintenance culture.
[0056] In some embodiments, in step 5), the culture is carried out for 10 h, 11 h, 12 h, 13 h, 14 h, 15 h, 16 h, 17 h, 18 h, 19 h, 20 h, 21 h, 22 h, 23 h, 24 h, 25 h, 26 h, 27 h, 28 h, 29 h, 30 h, 31 h, 32 h, 33 h, 34 h, 35 h or 36 h, and then the first culture medium is replaced with the second culture medium for maintenance culture.
[0057] In some embodiments, the subject generally refers to an organism.
[0058] In some embodiments, the subject can be an animal. Exemplary animals include, but are not limited to, humans; experimental animals such as mice, rats, monkeys, and chimpanzees; domestic animals such as dogs and cats; agricultural animals such as cattle, horses, pigs, sheep, goats; and wild animals such as bears, lions, tigers, leopards, elephants, zebras, giraffes, gorillas, dolphins, and whales.
[0059] According to another aspect of the present disclosure, a kit is provided for use in the method for enriching and culturing circulating tumor cells of the present disclosure.
[0060] In some embodiments, the kit includes the first culture medium and the second culture medium disclosed above.
[0061] According to another aspect of the present disclosure, provided are the method for enriching and culturing circulating tumor cells and the use of the kit for enriching and culturing circulating tumor cells.
[0062] In some embodiments, the circulating tumor cells (CTCs) are metastatic CTCs.
[0063] In some embodiments, the CTC may include, but is not limited to, acute leukemia cells, acute T-cell leukemia cells, acute lymphocytic leukemia cells, acute myeloid leukemia cells, myeloblastic leukemia cells, promyelocytic leukemia cells, myelomonocytic leukemia cells, monocytic leukemia cells, erythroleukemia cells, chronic leukemia cells, chronic myeloid (granulocytic) leukemia cells, chronic lymphocytic leukemia cells, polycythemia vera cells, lymphoma cells, multiple myeloma cells, Waldenstrom's macroglobulinemia cells, heavy chain disease cells, sarcoma cells, fibrosarcoma cells, myxosarcoma cells, liposarcoma cells, chondrosarcoma cells, osteoblastic sarcoma cells, lymphangiosarcoma cells, mesothelioma cells, Ewing's tumor cells, cell), leiomyosarcoma cell, rhabdomyosarcoma cell, colon cancer cell, colorectal cancer cell, pancreatic cancer cell, breast cancer cell, ovarian cancer cell, ovarian yolk sac tumor cell, prostate cancer cell, castration resistant prostate cancer cell, squamous cell carcinoma cell, basal cell carcinoma cell, adenocarcinoma cell, sweat gland carcinoma cell, sebaceous gland carcinoma cell, papillary carcinoma cell, papillary adenocarcinoma cell, cystadenocarcinoma cell, medullary carcinoma cell, bronchogenic cell, renal cell carcinoma cell, hepatoma cell, bile duct carcinoma cell, choriocarcinoma cell, seminoma cell, embryonal carcinoma cell, Wilms' tumor cell cell), cervical cancer cell, uterine cancer cell, testicular tumor cell, lung cancer cell, small cell lung cancer cell, bladder cancer cell, epithelial cancer cell, glioma cell, craniopharyngioma cell, ependymoma cell, pinealoma cell, hemangioblastoma cell, acoustic neuroma cell, oligodendroglioma cell, meningioma cell, melanoma cell, neuroblastoma cell, retinoblastoma cell, endometrial cancer cell, non-small cell lung cancer cell, head and neck cancer cell, or renal cancer cell.
[0064] In a specific embodiment, the circulating tumor cell (CTC) is an ovarian yolk sac tumor cell.
[0065] Compared with the prior art, the culture method of the present invention can quickly and easily separate and culture circulating tumor cell lines, and obtain a huge number of circulating tumor cells that are easy to store and expand. This method provides a powerful tool for in-depth research on the natural occurrence of circulating tumor cells and finding new circulating tumor cell markers and drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1The cell growth curve of the yolk sac tumor CTC cell line cultured in Example 1 is shown, wherein the abscissa is the cell growth generation, and the ordinate is the cell count number.
[0067] Figure 2 The microscopic observation image of the P3 generation yolk sac tumor CTC cell line of Example 1 is shown.
[0068] Figure 3 The microscopic observation image of the P4 generation yolk sac tumor CTC cell line of Comparative Example 1 is shown.
[0069] Figure 4 The microscopic observation image of the P1 generation yolk sac tumor CTC cell line of Comparative Example 2 is shown. DETAILED DESCRIPTION
[0070] Yolk sac tumor is a common histological subtype of ovarian malignant germ cell tumor, which is common in adolescents and young women. The histological structure of yolk sac tumor under microscopy is diverse, and the most common and typical is microcystic or sieve-like structure. The treatment strategy of ovarian yolk sac tumor is similar to that of other malignant GCTs, mainly including surgery and chemotherapy. Due to the early age of onset, most patients undergo fertility-preserving surgery, that is, preserving the healthy ovary and uterus. Whether or not to remove lymph nodes is still controversial. The results of previous retrospective studies have shown that systematic lymph node dissection does not improve the prognosis of GCT. Therefore, it is recommended to remove only the palpable enlarged lymph nodes after intraoperative exploration. Regardless of the stage, patients with yolk sac tumor should receive chemotherapy after surgery. The first-line chemotherapy regimen recommended by the NCCN guidelines is cisplatin / etoposide / bleomycin. Most patients can achieve a cure by receiving regular, adequate, and timely chemotherapy after surgery. However, the side effects of chemotherapy drugs on the fertility of young patients, irreversible damage to organs such as the lungs, and increased incidence of secondary tumors cannot be ignored. Compared with other histological subtypes, the prognosis of yolk sac tumor is relatively poor. Due to the lack of effective treatment, more than half of the recurrent patients eventually die from disease progression.
[0071] Therefore, early diagnosis, staging, and treatment of yolk sac tumor are of great significance. However, there are very few studies on yolk sac tumor. Similar to most solid tumors, yolk sac tumor will continue to shed tumor cells, and some of the shed cells can enter the blood circulation system and are called circulating tumor cells. Circulating tumor cells are the key medium for the metastasis of malignant tumors through the blood. If the specific markers and biological characteristics of circulating tumor cells can be determined, it is expected to establish new methods for diagnosing tumor metastasis risk, and even develop specific drugs to reduce the incidence of tumor metastasis.
[0072] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is described in detail in some embodiments in conjunction with the following embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0073] Examples and drawings are provided below to help understand the present invention. However, it should be understood that these examples and drawings are only used to illustrate the present invention, but do not constitute any limitation. The actual protection scope of the present invention is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present invention.
[0074] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is described in detail in some embodiments in conjunction with the following embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0075] Examples and drawings are provided below to help understand the present invention. However, it should be understood that these examples and drawings are only used to illustrate the present invention, but do not constitute any limitation. The actual protection scope of the present invention is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present invention.
[0076] Example
[0077] Experimental Materials
[0078] 1) Screening medium preparation: 50 mL of FBS solution (10%) (Sijiqing), 1.1 mg of bFGF (Sino Biological), 1.1 mg of EGF (Sino Biological), 60.5 mg of sodium pyruvate (Thermo Scientific), 80.38 mg of L-glutamine (Solarbio), and 11 mL of penicillin-streptomycin mixture (Gibco) were added to H-DMEM (Solarbio) to a total volume of 500 mL. After mixing, the mixture was filtered using a 0.22 μm syringe filter.
[0079] 2) Maintenance medium preparation: 50 mL KSR solution (Thermo Scientific), 1.1 mg bFGF (Sino Biological), 1.1 mg EGF (Sino Biological), 60.5 mg sodium pyruvate (Thermo Scientific), and 80.38 mg L-glutamine (Solarbio) were added to Knockout-DMEM (Thermo Scientific) to a total volume of 500 mL. After mixing, the mixture was filtered using a 0.22 μm syringe filter.
[0080] Example 1. Methods and steps for isolating and culturing circulating tumor cells of yolk sac tumor
[0081] 1) Sample collection: Peripheral blood or peritoneal fluid samples were obtained from clinical patients with ovarian yolk sac tumor. Depending on the source of the sample, 5-10 mL of peripheral blood and 25-50 mL of peritoneal fluid were collected.
[0082] 2) Sample pretreatment: The samples were treated with human peripheral blood lymphocyte separation medium (Solarbio) (800 g / 30 min / 25° C., ACC: 9, DEC: 0) to obtain a nucleated cell layer (or PBMC layer) containing CTCs.
[0083] 3) Add an equal volume of sterile PBS (Sanggong) to the PBMC solution at a ratio of 1:1, mix well and centrifuge again (120g / 10min / 25°C).
[0084] 4) The supernatant was removed to obtain the cell pellet, and 10 mL of sterile PBS (Sangong) was added to resuspend the cell pellet.
[0085] 5) Use a pipette to add 10 mL of sample into the sample slot of the disposable cell separation and enrichment collector (Labyrinthbiotech Co.LCC, LABYRINTH-K01), and place the collector into the slide compartment of the cell sorter (Labyrinthbiotech Co.LCC, LABYRINTH-CE01), and click to start the run. After 15 minutes, wait for the machine to finish running, open the slide compartment, take out the collector, and take out the detachable cell collection tube.
[0086] 6) After the sample is obtained by enrichment and sorting, it is resuspended in screening medium after centrifugation, and the cells are counted and statistically analyzed. The cells are inoculated into a six-well plate for culture, and the six-well plate is placed in an incubator at 37°C and 5% CO2 for 24 hours. At this time, the cells are at the P1 generation.
[0087] 7) After 24 hours of culture, remove the waste liquid from the six-well plate and continue culturing using the maintenance medium.
[0088] 8) After 48 hours of culture, the cells were subcultured according to the cell density. The cells were digested with 0.25% trypsin (Solarbio), resuspended with screening medium, and appropriate culture flasks were selected according to the number of cells, such as T25 and T75 culture flasks, and the cells were counted. At this time, the cells were at the P2 generation.
[0089] 9) After subculturing to T25 culture flasks for 24 hours, the waste liquid in the culture flasks was replaced with maintenance medium to accelerate cell proliferation.
[0090] 10) After 24 hours, harvest the cells, which are now at the P3 generation, count the cells, and calculate the proliferation multiples. Dilute the cells appropriately and inoculate them into multiple T75 culture flasks. Refer to steps 8) to 9) for the passaging method.
[0091] 11) After subculturing to T75 culture flasks for 24 hours, the waste liquid in the culture flask was replaced with maintenance medium to accelerate cell proliferation.
[0092] 12) After 24 hours, harvest the cells, which are now at the P4 generation, count the cells, and calculate the proliferation multiples. Dilute the cells appropriately and inoculate them into multiple T75 culture flasks. Refer to steps 8) to 9) for the passaging method.
[0093] 13) After subculturing the cells in T75 culture flasks for 24 hours, the waste liquid in the culture flasks was replaced with maintenance medium to accelerate cell proliferation.
[0094] 14) After 24 hours, harvest the cells, which are now at the P5 generation, count the cells, and calculate the proliferation multiples. Dilute the cells appropriately and inoculate them into multiple T75 culture flasks. Refer to steps 8) to 9) for the passaging method.
[0095] Comparative Example 1
[0096] The method is the same as that of Example 1 except that steps 6) to 9), 11) and 13) all use a culture medium having a formula of RPMI-1640 culture medium (Corning) + 10% FBS (Sijiqing) + 1% penicillin-streptomycin mixture (Gibco).
[0097] Comparative Example 2
[0098] The method is the same as that in Example 1 except that steps 6) to 9), 11) and 13) all use a culture medium having a formula of RPMI-1640 culture medium (Corning) + 20% FBS (Sijiqing) + 20 ng / mL EGF (Sino Biological) + 20 ng / mL bFGF (Sino Biological) + 2% penicillin-streptomycin mixture (Gibco).
[0099] Comparative Example 3
[0100] Except that screening culture medium is used in steps 6) to 9), 11) and 13), the other methods are the same as those in Example 1.
[0101] Comparative Example 4
[0102] Except that maintenance culture medium is used in steps 6) to 9), 11) and 13), the other methods are the same as those in Example 1.
[0103] Experimental Example 1 Comparative Experiment of Basic Culture Medium
[0104] The cells cultured in Example 1, Comparative Example 1 and Comparative Example 2 were counted and observed under a microscope.
[0105] The cell counting results of the third generation (P3) cells cultured in Example 1 showed that the cell number was >1×10 5 , cells proliferate massively, and the cell growth curve is shown in Figure 1 The morphology of the third generation (P3) cells was observed using an ordinary optical microscope. Figure 2 .
[0106] The cell counting results of the 4th generation (P4) cells cultured in Comparative Example 1 showed that the number of cells was less than 20, the survival rate was about 10%, and the cells survived by adhering to the wall but did not proliferate. The morphology of the 4th generation (P4) cells was observed using an ordinary optical microscope. Figure 3 .
[0107] The cell counting results of the first generation (P1) cells cultured in Comparative Example 2 showed that the number of cells was less than 100, the cells had very little proliferation, the cells were aging, and the growth state was poor. After 24 hours of continuous culture, the number of cells decreased to about 15, and the number of attached cells was small. The morphology of the first generation (P1) cells was observed using an ordinary optical microscope. Figure 4 .
[0108] Experimental Example 2 Comparative experiment of using culture medium alone and using two culture media in combination
[0109] Cells of the 1st to 5th generations (P1 to P5) of Example 1, Comparative Example 3 and Comparative Example 4 were taken and cell counting was performed. The experimental results are shown in Tables 1 and 2.
[0110] Table 1 Statistics of cell number per generation
[0111] <![CDATA[Number (×10 4 )]]> P1 P2 P3 P4 P5 Example 1 0.1 2.03 10.4 60.14 180.7 Comparative Example 3 0.1 0.5 2.4 10.2 20.31 Comparative Example 4 0.1 0.8 3.1 15.2 35.2
[0112] Table 2 Cell proliferation times
[0113]
[0114] Note: Cell proliferation multiple = Pn / P(n-1), where n>1.
[0115] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. A method for enriching and culturing circulating tumor cells, the method comprising the following steps: 1) Collect samples; 2) enriching circulating tumor cells from the sample; 3) using a first culture medium to resuspend the enriched circulating tumor cells and culture them to obtain a first culture product, wherein the first culture medium comprises a basal culture medium and 5% to 20% serum; and 4) Using a second culture medium to replace the first culture medium for maintenance culture to obtain a second culture product, wherein the second culture medium comprises a basal culture medium and 5% to 20% of a serum replacement.
2. The method according to claim 1, characterized in that The sample in step 1) is from a subject who has or has had a solid tumor, soft tissue tumor, hematopoietic tumor, glandular tumor or metastatic tumor; Preferably, the sample in step 1) comprises body fluid or a derivative thereof; Preferably, the sample in step 1) is selected from one or more of blood, plasma, serum, lymph, saliva, urine, sweat or ascites; Preferably, the sample in step 1) is ascites; Preferably, the circulating tumor cells in step 2) are metastatic circulating tumor cells; Preferably, the circulating tumor cells include one or more of the following: acute leukemia cells, acute T-cell leukemia cells, acute lymphocytic leukemia cells, acute myeloid leukemia cells, myeloblastic leukemia cells, promyelocytic leukemia cells, myelomonocytic leukemia cells, monocytic leukemia cells, erythroleukemia cells, chronic leukemia cells, chronic myeloid leukemia cells, chronic lymphocytic leukemia cells, polycythemia vera cells, lymphoma cells, multiple myeloma cells, Waldenstrom's macroglobulinemia cells, heavy chain disease cells, sarcoma cells, fibrosarcoma cells, myxosarcoma cells, liposarcoma cells, chondrosarcoma cells, osteoblastic sarcoma cells, lymphangiosarcoma cells, mesothelioma cells, Ewing's tumor cells, leiomyosarcoma cells, rhabdomyosarcoma cells, colon cancer cells, colorectal cancer cells, pancreatic cancer cells, breast cancer cells, ovarian cancer cells cells, ovarian yolk sac tumor cells, prostate cancer cells, castration-resistant prostate cancer cells, squamous cell cancer cells, basal cell cancer cells, adenocarcinoma cells, sweat gland cancer cells, sebaceous gland cancer cells, papillary cancer cells, papillary adenocarcinoma cells, cystadenocarcinoma cells, medullary cancer cells, bronchogenic cells, renal cell carcinoma cells, hepatoma cells, bile duct cancer cells, choriocarcinoma cells, seminoma cells, embryonal carcinoma cells, Wilms' tumor cells, cervical cancer cells, uterine cancer cells, testicular tumor cells, lung cancer cells, small cell lung cancer cells, bladder cancer cells, epithelial cancer cells, glioma cells, craniopharyngioma cells, ependymoma cells, pinealoma cells, hemangioblastoma cells, acoustic neuroma cells, oligodendroglioma cells, meningioma cells, melanoma cells, neuroblastoma cells, retinoblastoma cells, endometrial cancer cells, non-small cell lung cancer cells, head and neck cancer cells, or renal cancer cells; Preferably, the circulating tumor cells are ovarian yolk sac tumor cells.
3. The method according to claim 1, characterized in that The basal culture medium is selected from M199 culture medium, DMEM / F12 culture medium, IMDM culture medium, DMEM culture medium, high-glucose DMEM culture medium or Knockout-DMEM culture medium; Preferably, the first culture medium and / or the second culture medium comprises a high-glucose DMEM culture medium; Preferably, the second culture medium and / or the second culture medium comprises Knockout-DMEM medium; Preferably, the first culture medium and / or the second culture medium further comprises growth factors; Preferably, the first culture medium and / or the second culture medium further comprises one or more of the following growth factors: epidermal growth factor, nerve growth factor, brain-derived neurotrophic factor, fibroblast growth factor, stem cell factor, insulin-like growth factor or transforming growth factor-β; Preferably, the first culture medium and / or the second culture medium comprises 10-50 ng / mL of basic fibroblast growth factor; Preferably, the first culture medium and / or the second culture medium contains 10-50 ng / mL of epidermal growth factor.
4. The method according to claim 1, characterized in that: The serum includes fetal bovine serum, newborn calf serum, calf serum, human serum, horse serum, pig serum, rabbit serum, goat serum or rabbit serum; Preferably, the serum is fetal bovine serum; Preferably, the serum replacement comprises KnockOut TM serum replacement, N2 or B27; Preferably, the serum replacement is KnockOut TM Serum replacement.
5. The method according to claim 1, characterized in that The first culture medium comprises: H-DMEM culture medium, 5% to 20% FBS, 10 to 50 ng / mL FGF, 10 to 50 ng / mL EGF, 0.1 to 10 mM sodium pyruvate, 0.1 to 10 mM L-glutamine and 0% to 5% penicillin-streptomycin mixture; Preferably, the first culture medium comprises: H-DMEM culture medium, 10% FBS, 20 ng / mL FGF, 20 ng / mL EGF, 1 mM sodium pyruvate, 1 mM L-glutamine and 2% penicillin-streptomycin mixture; Preferably, the second culture medium comprises: knockout-DMEM culture medium, 5% to 20% KnockOut TM serum replacement, 10–50 ng / mL FGF, 10–50 ng / mL EGF, 0.1–10 mM sodium pyruvate, and 0.1–10 mM L-glutamine; Preferably, the second culture medium comprises: knockout-DMEM culture medium, 10% KnockOut TM serum replacement, 20 ng / mL FGF, 20 ng / mL EGF, 1 mM sodium pyruvate, and 1 mM L-glutamine.
6. The method according to claim 1, characterized in that In the step 3), the culture time is 10 to 36 hours; Preferably, in the step 3) of the method, after culturing with the first culture medium for 10 to 36 hours, the first culture medium is replaced with the second culture medium for maintenance culture.
7. The method according to claim 1, characterized in that The method further comprises the following steps: 5) After the second culture product is digested with trypsin, it is resuspended in the first culture medium and cultured; 6) using the second culture medium to replace the first culture medium for maintenance culture; 7) Optionally, repeat steps 5) and 6); Preferably, after culturing with the first culture medium for 10 to 36 hours, the first culture medium is replaced with the second culture medium for maintenance culture.
8. The method according to claim 1, characterized in that The subject includes an organism; Preferably, the subject includes humans, experimental animals, agricultural animals or wild animals; Preferably, the experimental animals include mice, rats, monkeys and chimpanzees; Preferably, the domestic animals include dogs, cats, rabbits, and pigs; Preferably, the agricultural animals include cattle, horses, pigs, sheep, and goats; Preferably, the wild animal comprises a bear, a lion, a tiger, a leopard, an elephant, a zebra, a giraffe, a gorilla, a dolphin or a whale.
9. A kit for use in the method for enriching and culturing circulating tumor cells disclosed herein.
10. The kit according to claim 9, characterized in that The kit includes the first culture medium and the second culture medium.
Citation Information
Cited By
Human PDAC ascites tumor cell strain and application thereof
CN119979464A
